Areas of research

Pfizer is constantly researching new medical compounds in a broad range of therapy areas:

Allergy & Respiratory

The efforts of the A&R team are concentrated on the lower airway diseases of Asthma and Chronic Obstructive Pulmonary Disease (COPD).

Infectious diseases

Pfizer is breaking new ground in our approaches to the treatment of HIV, and we are exploring a number of other approaches in research and development.

Cardiovascular, Metabolic and Endocrine Diseases

Pfizer’s current and future portfolio of medicines in this Therapeutic Area focuses on the control of the risk factors inherent in smoking, diet, physical inactivity, and Type 2 diabetes.

Pain

Pfizer's pain team is hopeful that new insights into the causes of pain, as well as how to actually 'measure' it, can help usher in a series of new medicines.

Dermatology

Pfizer's Dermatology TA is dedicated to developing new prescription medicines to help close the gap in the availability of effective skin care products.

Gastrointestinal & Hepatology

Pfizer is dedicated to discovering new treatments for diseases that affect the gastrointestinal tract and the liver.

Inflammation

Some of our most important candidates are derived from our leading-edge work in identifying kinases—enzymes that "switch on" other enzymes.

Pfizer has new approaches to attack Alzheimer’s disease, schizophrenia and other feared conditions. For anxiety, sleep disorders, and neuropathic pain, we continue to expand inquiry into alpha-2-delta binding site agents.

Oncology

The Pfizer portfolio contains medicines currently being investigated for the treatment of stomach, liver, prostate, pancreas and melanoma forms of cancer.

Ophthalmology

Pfizer is building on its expertise in treating diseases of the eye, including glaucoma and retinal diseases, such as age-related macular degeneration (AMD) and diabetic macular edema (DME).

Genitourinary

Our goal is to restore dignity to those suffering from GU conditions and help improve their quality of life.